CounterX Therapeutics

CounterX Therapeutics is a biotechnology company focused on leveraging the "dark matter" of the human genome, specifically Human Endogenous Retroviruses (HERVs), to develop novel therapeutics for cancer and inflammatory diseases. Founded on pioneering research from the Francis Crick Institute, the company utilizes a proprietary platform to identify HERV-derived antigens that are selectively expressed in diseased tissues. By targeting these viral remnants, CounterX aims to create highly specific therapies, including monoclonal antibodies, that can trigger potent immune responses against tumors. The company's approach represents a frontier in precision medicine, turning ancient viral sequences into modern therapeutic targets. It is backed by prominent life science investors including SV Health Investors and Omega Funds.